Founded in 1995, LSBio was established as a molecular pathology company with a focus on protein localisation in diseased human tissues by IHC. Through the experience gained by executing thousands of IHC studies, and generating and testing many thousands of antibodies, LSBio has become a world leader in the antibody industry, with a reputation for excellence. LSBio has a catalog of 130,000 monoclonal and polyclonal antibodies. Antibodies are available for most species and all major research applications, such as immunoblotting, IHC, immunofluorescence, and fluorescence-activated cell sortingThrough extensive ongoing in-house testing more than 10,000 of these antibodies have been further validated specifically for use under LSBio's standardised IHC conditions against formalin-fixed paraffin-embedded human tissues. These are LSBio's premier IHC-plus™ brand antibodies.Each antibody is tested at multiple concentrations on more than 20 normal human tissue types, and when appropriate multiple normal brain regions and/or cancer types. LSBio's IHC protocol has been developed over the past 15 years as the most optimal method of immunolabeling FFPE tissues, the most common fixation method used by pathology labs worldwide. A LifeSpan pathologist, with extensive experience evaluating IHC, analyzes the localization profile of each antibody, identifying positive and negative cell types, signal strength, subcellular and extracellular staining, and staining artifacts. This information is then compared with all published expression and localisation data available for the protein. This enables LSBio to evaluate how each antibody behaves in IHC, including its specificity to the target protein, its sensitivity of detection, and any non-specific staining characteristics that it may display. In order to be selected as an IHC-plus™ brand antibody, antibodies must have a close correlation to the published literature, be high affinity, display minimal staining artifacts, and have a high signal-to-noise ratio, such that its specific staining is considerably higher than its level of nonspecific background staining.In the years to come, LSBio plans to continue expanding its catalog of high-quality proteomics products, with a focus on IHC-validated antibodies, providing its customers with excellent reagents to accelerate their research.